Through the first half of 2024, orthopedic investment activity is on pace for a rebound and one of its busiest years in nearly a decade.

Orthopedic Funding on Pace to Accelerate in 2024

Through the first half of 2024, orthopedic investment activity is on pace for a rebound and one of its busiest years in nearly a decade.

The Numbers
The increasing importance of technology ecosystems in the spine market could mean that a large population of smaller companies are at risk.

Are Smaller Spine Companies at Risk in a Changing Landscape?

The increasing importance of technology ecosystems in the spine market could mean that a large population of smaller companies are at risk.

Orthopedic Market Growth

Enovis on Track for $1 Billion Recon Business

Enovis’ reconstructive segment accounted for just 22% of sales in 2019. It will account for nearly 50% as it reaches $1 billion in 2024.

Orthoflash®
Smith+Nephew CATALYSTEM Primary Hip
Smith+Nephew Gains 510(k) for CATALYSTEM Primary Hip

CATALYSTEM addresses the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers.

,
NextStep TheRa™ Collared and Collarless Hip
NextStep Arthropedix to Launch TheRay Hip System

TheRay is designed to match anatomical variations and consistencies for optimal biomechanical reconstruction.

,
DiscGenics IDCT Injection
DiscGenics to Study Cell Therapy for Degenerative Disease

The company gained FDA approval to proceed with Phase III clinical evaluation of allogeneic, injectable disc progenitor cell therapy for symptomatic lumbar degenerative disc disease.

,
illustration biologic matrix orange
Paradigm BioDevices Launches VisiCORE for Bone Graft Harvesting

VisiCORE is a bone graft harvesting system for foot and ankle fusion designed with a clear collection tube with proprietary Graft Retention Technology.

,
Cytonics initiated enrollment to study a recombinant variant of the alpha-2-macroglobulin blood serum protein to treat cartilage degradation.
Phase 1 Clinical Study For CYT-108 in Knee OA

Cytonics initiated enrollment to study a recombinant variant of the alpha-2-macroglobulin blood serum protein to treat cartilage degradation.

,
Competitive Landscape
Industry Voices

Contact Us

0